The Negative Prognostic Impact of Derivative 9 Deletions in Patients Who Received Hydroxyurea Treatment for Chronic Myelogenous Leukemia in the Chronic Phase

Publisher： Karger

E-ISSN： 2296-5262|31|11|585-589

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.31, Iss.11, 2008-10, pp. : 585-589

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long‐term 9‐year follow‐up of 134 patients

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 5, 2015-05 ,pp. : E95-E96

John Wiley & Sons Inc

Access to resources Recommend Favorite

Hydroxyurea‐Related Leg Ulcers in a Patient with Chronic Myelogenous Leukemia: A Case Report and Review of the Literature

By  

THE JOURNAL OF DERMATOLOGY, Vol. 26, Iss. 1, 1999-01 ,pp. : 56-62

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dasatinib for the treatment of chronic phase chronic myeloid leukemia

By Campbell Victoria   Copland Mhairi  

Clinical Practice, Vol. 10, Iss. 4, 2013-07 ,pp. : 415-425

Future Medicine

Access to resources Recommend Favorite

Impact of Bone Marrow Morphology on Multivariate Risk Classification in Chronic Myelogenous Leukemia

By  

Acta Haematologica, Vol. 109, Iss. 1, 2002-12 ,pp. : 53-56

Karger

Access to resources Recommend Favorite

Promyelocytic Blast Crisis of Chronic Myelogenous Leukemia during Imatinib Treatment

By  

Acta Haematologica, Vol. 117, Iss. 4, 2007-02 ,pp. : 236-237

Karger

Access to resources Recommend Favorite